Ottimo Pharma is a private biotechnology company, co-founded in 2020 by Medicxi and Jonny Finlay, focused on the development of pioneering innovative cancer therapies for solid tumors. The Company's lead program, Jankistomig, is a PD1-VEGFR2 bi-functional antibody designed to target both immune checkpoint inhibition and angiogenesis in a single IgG therapy. By advancing this dual-pathway approach, Ottimo Pharma aims to improve cancer treatment outcomes and reduce overall healthcare burden. The Company boasts a world-class leadership team, including David Epstein as Chair and CEO, Mehdi Shahidi as Head of Development and CMO, and James Sabry as Vice-Chair of the Board. Ottimo Pharma anticipates filing an IND in late 2025.

Biotechnology

Health Care

Life Sciences

Therapeutics

Ottimo Pharma

David Epstein

Rick Anderson

Spencer Fisk

Katherine Bell-McGuinn

Ling Zeng

This department manages and oversees clinical operations, ensuring effective execution of clinical trials and research initiatives.

Clinical Operations

This department oversees the research and advancement of clinical programs and strategies.

Clinical Development

This department manages the organization's financial planning, analysis, reporting, and oversight.

Finance Department

This department oversees the development and manufacturing processes to ensure efficient technical operations.

Ottimo Pharma

Org chart

Teams

Clinical Operations

Clinical Development

Finance Department

Technical Operations

Offices

Ottimo Pharma

Org chart

Teams

Clinical Operations

Clinical Development

Finance Department

Technical Operations

Offices

Related companies